Alexander Drilon,Geoffrey R Oxnard,Daniel S W Tan,Herbert H F Loong,Melissa Johnson,Justin Gainor,Caroline E McCoach,Oliver Gautschi,Benjamin Besse,Byoung C Cho,Nir Peled,Jared Weiss,Yu-Jung Kim,Yuichiro Ohe,Makoto Nishio,Keunchil Park,Jyoti Patel,Takashi Seto,Tomohiro Sakamoto,Ezra Rosen,Manisha H Shah,Fabrice Barlesi,Philippe A Cassier,Lyudmila Bazhenova,Filippo De Braud,Elena Garralda,Vamsidhar Velcheti,Miyako Satouchi,Kadoaki Ohashi,Nathan A Pennell,Karen L Reckamp,Grace K Dy,Jürgen Wolf,Benjamin Solomon,Gerald Falchook,Kevin Ebata,Michele Nguyen,Binoj Nair,Edward Y Zhu,Luxi Yang,Xin Huang,Elizabeth Olek,S Michael Rothenberg,Koichi Goto,Vivek Subbiah,Geoffrey R. Oxnard,Daniel S.W. Tan,Herbert H.F. Loong,Caroline E. McCoach,Byoung C. Cho,Manisha H. Shah,Philippe A. Cassier,Nathan A. Pennell,Karen L. Reckamp,Grace K. Dy,Edward Y. Zhu,S. Michael Rothenberg

Abstract:BACKGROUND: RET fusions are oncogenic drivers in 1 to 2% of non-small-cell lung cancers (NSCLCs). In patients with RET fusion-positive NSCLC, the efficacy and safety of selective RET inhibition are unknown.METHODS: We enrolled patients with advanced RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated separately in a phase 1-2 trial of selpercatinib. The primary end point was an objective response (a complete or partial response) as determined by an independent review committee. Secondary end points included the duration of response, progression-free survival, and safety.RESULTS: In the first 105 consecutively enrolled patients with RET fusion-positive NSCLC who had previously received at least platinum-based chemotherapy, the percentage with an objective response was 64% (95% confidence interval [CI], 54 to 73). The median duration of response was 17.5 months (95% CI, 12.0 to could not be evaluated), and 63% of the responses were ongoing at a median follow-up of 12.1 months. Among 39 previously untreated patients, the percentage with an objective response was 85% (95% CI, 70 to 94), and 90% of the responses were ongoing at 6 months. Among 11 patients with measurable central nervous system metastasis at enrollment, the percentage with an objective intracranial response was 91% (95% CI, 59 to 100). The most common adverse events of grade 3 or higher were hypertension (in 14% of the patients), an increased alanine aminotransferase level (in 12%), an increased aspartate aminotransferase level (in 10%), hyponatremia (in 6%), and lymphopenia (in 6%). A total of 12 of 531 patients (2%) discontinued selpercatinib because of a drug-related adverse event.CONCLUSIONS: Selpercatinib had durable efficacy, including intracranial activity, with mainly low-grade toxic effects in patients with RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated. (Funded by Loxo Oncology and others; LIBRETTO-001 ClinicalTrials.gov number, NCT03157128.).

What problem does this paper attempt to address?

The problem this paper attempts to address is the evaluation of the efficacy and safety of the selective RET inhibitor selpercatinib in patients with RET fusion-positive non-small cell lung cancer (NSCLC). Specifically, the researchers aim to understand the performance of selpercatinib in the following categories of patients: 1. **RET fusion-positive NSCLC patients who have previously received platinum-based chemotherapy**: These patients have typically undergone multiple treatments with limited efficacy and have a high risk of brain metastases. 2. **RET fusion-positive NSCLC patients who have not received any treatment**: These patients are receiving selpercatinib for the first time, and the researchers aim to understand its efficacy in treatment-naive patients. ### Background RET fusion is an oncogenic driver in 1% to 2% of non-small cell lung cancers. The efficacy and safety of selective RET inhibitors in RET fusion-positive NSCLC patients have not been clearly established. Previously used multi-target kinase inhibitors (such as cabozantinib and vandetanib) have shown some inhibitory effects on RET, but their clinical efficacy is limited due to poor pharmacokinetic properties and severe side effects caused by multi-target inhibition. ### Methods The researchers conducted a phase 1-2 clinical trial, enrolling RET fusion-positive NSCLC patients who had previously received platinum-based chemotherapy and those who had not received any treatment. The primary endpoint was the objective response rate (complete or partial response) determined by an independent review committee. Secondary endpoints included duration of response, progression-free survival, and safety. ### Results - **Patients who had previously received platinum-based chemotherapy**: - The objective response rate was 64% (95% confidence interval: 54% to 73%), with a median duration of response of 17.5 months. - 63% of patients continued to respond at a median follow-up of 12.1 months. - Among 11 patients with measurable central nervous system metastases at baseline, the intracranial objective response rate was 91% (95% confidence interval: 59% to 100%). - **Patients who had not received any treatment**: - The objective response rate was 85% (95% confidence interval: 70% to 94%), with 90% of patients continuing to respond at 6 months. - The median duration of response and progression-free survival were not reached. ### Safety The most common grade 3 or higher adverse events included hypertension (14% of patients), elevated alanine aminotransferase levels (12% of patients), elevated aspartate aminotransferase levels (10% of patients), hyponatremia (6% of patients), and lymphopenia (6% of patients). Twelve patients (2%) discontinued treatment due to drug-related adverse events. ### Conclusion Selpercatinib demonstrated durable efficacy, including intracranial activity, in both previously treated and treatment-naive RET fusion-positive NSCLC patients, with primarily low-grade toxicity. This suggests that selpercatinib may be a potent treatment option for this patient population.

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.

Efficacy and Safety of Selpercatinib in Chinese Patients with Advanced RET Fusion-Positive Non-Small-cell Lung Cancer: a Phase II Clinical Trial (LIBRETTO-321).

FP14.05 LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).

1413Tip LIBRETTO-431: Selpercatinib in Treatment (Tx)-Naïve Patients with RET Fusion-Positive (RET+) Non-Small Cell Lung Cancer (NSCLC)

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated <i>RET</i> positive non-small-cell lung cancer

Phase III study of selpercatinib vs chemotherapy plus /- pembrolizumab in untreated <i>RET</i> positive non-small-cell lung cancer

Selpercatinib or Chemotherapy in <i>RET</i> Fusion-Positive NSCLC

Intracranial Outcomes of 1L Selpercatinib in Advanced RET Fusion-Positive NSCLC: LIBRETTO-431 Study.

Intracranial Activity of Selpercatinib in Chinese Patients With Advanced <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial

Efficacy and Safety of 1L Selpercatinib in RET Fusion-Positive NSCLC: LIBRETTO-431 East Asian Subgroup Analysis.

Durable efficacy of selpercatinib in patients with RET fusion+ solid tumors, with a focus on GI tumors: LIBRETTO-001.

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced <i>RET</i> fusion-positive non-small-cell lung cancer and thyroid cancer, and <i>RET</i>-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial

CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non–Small Cell Lung Cancer

Health-related Quality of Life (hrqol) and Symptoms in LIBRETTO-431 Patients with RET Fusion-Positive Advanced Non-Small-cell Lung Cancer (NSCLC).

Selpercatinib Monotherapy in a Chinese Patient with RET Fusion/ EGFR Co-Mutated Nonsmall Cell Lung Cancer from the Phase II LIBRETTO-321 Study: a Case Report.

Efficacy and Safety of Selpercatinib in Chinese Patients with Advanced RET-altered Thyroid Cancers: Results from the Phase II LIBRETTO-321 Study

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer and thyroid cancer, and RET -mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial.

Efficacy and Safety of Selpercatinib in Treating RET-altered MTC: a Single-Arm Meta-Analysis

Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC

Efficacy and Safety of SY-5007, a Highly Potent and Selective RET Inhibitor, in Chinese Patients with Advanced RET-fusion Positive Non-Small Cell Lung Cancer (NSCLC): Results from a Multicenter, Single-Arm, Phase II Study.